Advanced Filters
noise
Found 1,281 clinical trials

Physical Activity Program for TRD

This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).

18 - 65 years of age All Phase N/A
K Katharine Dunlop, PhD

The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression

Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and brain function. For those with depression where medication and psychotherapy have limited benefit, repetitive …

18 - 65 years of age All Phase N/A
M Mario Farag, MD

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at …

22 - 70 years of age All Phase N/A

pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression

This study is a multicenter, randomized, double-blind, placebo-controlled trial aimed at exploring the effectiveness and safety of rTMS intervention with DMPFC targets guided by pBFS in patients with treatment-resistant depression.

18 - 65 years of age All Phase N/A
B Bernhard Baune

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available …

18 - 65 years of age All Phase 3
K Klaus Martiny, DMsc

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation. In …

18 - 75 years of age All Phase N/A
D Derrick Buchanan, PhD

Biomarker-guided rTMS for Treatment Resistant Depression

Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnetic resonance imaging (fMRI) to confirm a way …

22 - 65 years of age All Phase 3
B Botao Xiong, M.D.

Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation

Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss. Despite this, approximately 30% of patients do not respond to standard pharmacological or psychological treatments. Currently, we lack objective brain-based biomarkers to differentiate between natural mood …

18 - 65 years of age All Phase N/A
Z Z. Jeff Daskalakis, MD PhD

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in cases where patients have not responded well to traditional therapies. Treatment will be delivered over a 2-week period with daily weekday …

18 - 85 years of age All Phase N/A
C Cristina CC Colombo, MD

Ketamine Augmentation of ECT in Treatment-Resistant Depression

This is a randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating the additive effect of intravenous ketamine in combination with electroconvulsive therapy (ECT) in patients with treatment-resistant major depressive disorder (MDD). The study aims to determine whether ketamine enhances the antidepressant efficacy of ECT and reduces associated cognitive side effects. …

18 - 70 years of age All Phase 3

Simplify language using AI